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• Selective serotonin reuptake inhibitors (SSRI) may improve heart disease outcomes.
• Aortic regurgitation (AR) decreases systolic function.
• Paroxetine (SSRI) treatment effects were investigated in AR rats.
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Volume overloadDepression is a predictor of poor prognosis in patients with heart failure. Selective serotonin (5-HT) reuptake
inhibitors (SSRIs) may improve these outcomes. Left ventricular volume overload induced hypertrophy that is
associated with aortic regurgitation (AR) leads to ventricular dysfunction and heart failure. The aim of this
study was to verify the effects of the SSRI paroxetine on cardiac function, as well as on ﬂuid intake and excretion,
in subchronic AR.MaleWistar rats (260 to 280 g) received sham (SH) surgery or AR induced by retrograde punc-
ture of the aortic valve leaﬂets. The presence of AR was conﬁrmed by echocardiography (ECHO) exams. Four
weeks after AR surgery, subcutaneous injections of paroxetine (PAR: 10 mg/kg 3 times in a week) or saline
were administered. The rats were randomly divided into the following 4 groups and treated for 4 weeks:
AR-PAR, ARsaline, SH-PAR and SH-saline. At the end of the treatment period, fractional shorteningwas preserved
in AR-PAR, compared to AR-saline (46.6 ± 2.7% vs 38.3 ± 2.2%, respectively). Daily 0.3 M NaCl intake was
reduced in PAR-treated rats. Natriuresis was increased in weeks 2-3 after PAR treatment. Our results suggest
that augmentation of central 5-HT neurotransmission has a beneﬁcial effect on cardiovascular remodeling fol-
lowing volume overload. The mechanisms underlying this effect are unknown.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aortic regurgitation (AR) causes a progressive dilatation and hyper-
trophy of the left ventricle (LV). Over time, AR leads to LV dysfunction
and eventually heart failure after a prolonged lack of symptoms [1].
Valve heart disease remains a prevalent issue in Brazil, as this rheumatic
heart disease is a leading cause of AR, particularly in young patientscience editor and by a native
tiﬁcate Veriﬁcation Key: 28E4-
Institute of Bioscience, UNESP,
or s/n, 18618-000 Botucatu, SP,
).
. This is an open access article under[1,2]. Furthermore, its incidence is increasing in developed countries
as a consequence of senile degeneration [2]. Heart failure, independent
of underlying disease, is associatedwith the activation of several neuro-
transmitter systems that lead to further ventricular dysfunction and
death.
Depression, amooddisorder, is a co-morbidity commonly associated
with cardiovascular disease [3–5]. This medical condition also causes an
activation of neurohumoral systems, which could facilitate the transi-
tion to heart failure. Alterations in the metabolism of serotonin (5-HT)
are particularly implicated in this process [6,7]. Fourweeks of ﬂuoxetine
treatment, a selective serotonin reuptake inhibitor (SSRI), can prevent
cardiovascular changes associated with moderate chronic stress in rats
[7]. SSRIs are widely prescribed, and they show advantages over classic
antidepressants, including dose safety and good tolerability, as well asthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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probability of arrhythmias and platelet function [6,8]. Panic patients
treated with the SSRI paroxetine (PAR) present with increased heart
rate variability [9]. The administration of a selective 5-HT3 receptor
agonist in the forebrain exerts a tonic sympathoinhibitory action on
the pressor component of the baroreﬂex [10], suggesting a potential
beneﬁcial role for SSRI treatment in heart disease.
Sodium intake reductions are well recognized as important steps
to improve both the clinical outcome and the quality of life of cardiac
patients [11,12]. The involvement of 5-HT in sodium balance, intake
and excretion behaviors is well documented. The depletion of 5-HT
through intraperitoneal administration of p-chlorophenylalanine, an
amino acid that competes with tryptophan for the same transporter on
serotonergic neurons, increases sodium appetite in salt-depleted rats
[13]. Chemical lesions of the dorsal raphe nucleus, a midline structure
comprising themain source of central 5-HT [14], increase sodium intake
for a variety of protocols, for instance sodium depletion and angiotensin
II brain activation [15]. Taken these observations in account the present
study was designed to investigate the effects of PAR treatment in sub-
chronic AR in relation to heart function and ﬂuid intake and excretion.
2. Materials and methods
2.1. Animal model of AR
Male Wistar rats (260 to 280 g) had sham (SH) or AR surgeries in-
duced by retrograde puncture of the aortic valve leaﬂets under anesthe-
sia [ketamine 80 mg/kg of bodyweight (bw) plus xylazine 7mg/kg bw,
Vetbrands, Jacareí-SP]; these surgeries are described elsewhere [16,17].
One week after surgeries, the rats were analyzed by echocardiogram,fra
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Fig. 1. Fractional shortening (%) at the weeks 4 (above, before treatment) and 8 (below,
after treatment) in treated/untreated aortic regurgitation (AR) or sham (SH) rats. Data
are presented as the means ± SEM. A two-way ANOVA was performed for comparisons
between surgery and treatment.and the rats meeting the inclusion criteria (see below) were assigned
to experimental groups. The rats were randomly divided into 4 groups:
AR-PAR, AR-saline, SH-PAR and SH-saline. Drug treatmentwas initiated
4 weeks after the surgical procedure, as this is a period when the heart
has already been exposed to an overload that continues for 4weeks. An-
imals were observed daily to collect the drinking and weekly weight
data. At the end of the protocol, the animals were euthanized and
their hearts were removed and weighed. All procedures were in accor-
dancewith theAnimal Care andUse policies of the Institute of Biosciences
of Botucatu, which follows the Brazilian College of Animal Experimenta-
tion (COBEA) polices. All efforts were made to minimize animal discom-
fort and the number of animals used.
2.2. Echocardiography
A completeM-mode, 2D, andDoppler echocardiogram (ECHO)were
performed on the animals under anesthesia (ketamine 50 mg/kg with
xylazine 5 mg/kg) using a 12-MHz probe with a Sonos 5500 echograph
(Philips Medical Imaging, Andover, Mass) one week after surgery to
conﬁrm AR presence and severity. The ECHO was repeated at weeks 4
and 8 after surgery to collect morphofunctional variables. ECHO inclu-
sion criteria included a ratio of regurgitant jet width to LVOT diameter
N50% of a retrograde holo-diastolic ﬂow in the proximal descending
aorta (Fig. 1), and animals that failed tomeet these criteriawere exclud-
ed. We analyzed LV dimensions, wall thickness, ejection fraction, dia-
stolic function, and cardiac output (i.e., ejection volume in the LV
outﬂow tract-heart rate), as previously reported [18].
2.3. Drugs
Paroxetine chloride (PAR, 10 mg/kg bw, PharmaNostra, Rio de
Janeiro, Brazil) was dissolved in saline vehicle, which was used as
a control. PAR was injected subcutaneously (sc) every three days
over 4 weeks.
2.4. Daily water and 0.3 M NaCl intake and excretion
The rats were kept in individual metal cages. Water and 0.3 M NaCl
were provided from burettes with 1 ml divisions that were ﬁtted with
metal drinking spouts, with free access to a standard laboratory diet
(Labina Purina® Rat Chow). Temperature was maintained at 23 ±
2 °C and humidity at 54 ± 10% with a 12:12 light:dark cycle (onset at
06:10). During PAR treatment, the water and 0.3 M NaCl solution
volumes were measured daily. Overnight urine samples were col-
lected weekly from weeks 5–8. Each night, the animals were moved to
metabolic cages and given access only to water. Urine samples were ana-
lyzed by a ﬂame photometer to quantify Na+ and K+ in milliequivalents
(mEq). In order to calculate sodium and potassium excretion the urinary
volume was multiplied by the mEq.
2.5. Blood pressure and heart rate
Mean arterial pressure (MAP) and heart rate (HR) were recorded in
unanesthetized rats. Four days after collectingECHOvariables atweek 8,
the rats were anesthetized again with ketamine (80 mg/kg bw)
combined with xylazine (7 mg/kg bw), as described for AR surgeries.
After anesthesia onset, polyethylene tubing (PE-10 tube connected to
a PE-50 tube, Braintree Scientiﬁc, Inc. MA, USA) was inserted into the
abdominal aorta through the femoral artery. Arterial catheters were
tunneled sc and exposed on the back of the rats to allow access in
unrestrained, freely moving rats. To record pulsatile arterial pressure,
MAP andHR, the arterial catheterwas connected to a pressure transducer
(TSD104A, Biopac Systems) coupled to a pre-ampliﬁer (model M100A-
CE, Biopac Systems Santa Barbara, CA, USA), and monitored by a BIOPAC
computer data acquisition system.
Table 1
Echocardiographic data before paroxetine treatment, 4 weeks following AR.
Variables — 4
weeks
AR-PAR
n = 9
AR-saline
n = 8
SH-PAR
n = 9
SH-saline
n = 8
LVSD (mm) 5.13 ± 0.38* 5.12 ± 0.53* 3.46 ± 0.40 2.62 ± 0.26
LVDD (mm) 8.74 ± 0.31* 9.07 ± 0.39* 7.01 ± 0.33 5.95 ± 0.29
LAV (cm3) 0.180 ± 0.020* 0.189 ± 0.033* 0.075 ± 0.009 0.080 ± 0.019
Relative wall
thickness
0.39 ± 0.02 0.35 ± 0.02 0.43 ± 0.03 0.48 ± 0.01
LA/Ao 1.44 ± 0.11* 1.61 ± 0.13* 1.22 ± 0.06 1.05 ± 0.04
Sphericity
index
0.81 ± 0.01* 0.87 ± 0.02* 0.66 ± 0.02 0.63 ± 0.01
Body weight
(g)
378.4 ± 12.9 369.3 ± 6.2 371.3 ± 14.3 362.8 ± 9.9
LVSD = left ventricle end-systolic diameter (mm, p b 0.001); LVDD = left ventricle
end-diastolic diameter (mm, p b 0.01); LAV = left atrium volume (cm3, p b 0.01); LA/
Ao= left atriumnormalized area (p b 0.01). Treatment initiated after this ECHOmeasure-
ment. Data are presented as the means ± SEM. *Different from SH.
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Fig. 2. Comparison of the effect of time on fractional shortening (%) in weeks 4 and 8
in aortic regurgitation (AR) or sham (SH) rats. Data are presented as the means ± SEM. A
two-way repeated measures ANOVA was performed to compare AR or SH and time with
fractional shortening (%) as the dependent variable: AR, p = 0.041 and SH, p = 0.496.
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Two-way ANOVA was used to analyze the ECHO data, daily water
and 0.3 M NaCl intake, blood pressure and urinary variables for each
week of treatment, with surgery and treatment as independent factors.
Two-way repeated measures ANOVA was used to compare the effect of
time on the presence or absence of AR. Tests were combined with the
Student–Newman–Keuls post-hoc test when appropriate. A probability
of less than 0.05was required for signiﬁcance. Data are expressed as the
means ± standard error of the mean (SEM).
3. Results
3.1. Echocardiographic data
Tables 1 and 2 summarize the echocardiographic data for weeks
4 and 8, respectively. It was important to demonstrate that the groups
were homogeneous before the PAR treatment. A 4-week treatment
period prevented a further reduction in LV function in the AR-PAR
group, comparedwith AR-saline (Figs. 1 and 2). That is, fractional short-
ening in AR-PARwas similar to the control groups,whereas it decreased
in the AR-saline group (Fig. 1). Interestingly, this protective effect
occurred in association with decreases in daily sodium intake,
even in the presence of LV dilation. PAR treatment prevented a time-
dependent progression of LV dysfunction in the AR rats (Fig. 2), data are
represented asmedian andpercentiles and a two-way repeatedmeasures
ANOVA was performed to compare treatment and time and highlight
the differences in the time evolution of the AR–PAR and AR–saline on
fractional shortening (%). However, PAR had no effect on the LV function
index in rats without cardiac dysfunction (Fig. 2).Table 2
Echocardiographic data at the end of paroxetine treatment, 8 weeks following AR.
Variables — 8
weeks
AR-PAR
n = 9
AR-saline
n = 8
SH-PAR
n = 9
SH-saline
n = 8
LVSD (mm) 4.73 ± 0.35*+ 5.86 ± 0.45* 3.84 ± 0.23 2.85 ± 0.22
LVDD (mm) 8.82 ± 0.33* 9.45 ± 0.54* 7.54 ± 0.17 6.71 ± 0.15
LAV (cm3) 0.168 ± 0.019* 0.164 ± 0.018* 0.102 ± 0.009 0.065 ± 0.009
Relative wall
thickness
0.34 ± 0.02* 0.35 ± 0.03* 0.37 ± 0.03 0.41 ± 0.03
LA/Ao 1.38 ± 0.08* 1.57 ± 0.05* 1.15 ± 0.04 1.26 ± 0.07
Sphericity
index
0.806 ± 0.026* 0.856 ± 0.017* 0.670 ± 0.024 0.637 ± 0.031
Body weight
(g)
431.9 ± 19.8 419.5 ± 7.4 448.2 ± 19.3* 414.0 ± 14.1
LVSD= left ventricle end-systolic diameter (mm, p b 0.001 for surgery and p= 0.003 for
treatment); LVDD = left ventricle end-diastolic diameter (mm, p b 0.01); LAV = left
atrium volume (cm3, p b 0,01); LA/Ao = left atrium normalized area (p b 0.01). Data are
presented as the means ± SEM. *Different from SH, +different from AR-saline.3.2. Fluid balance
Daily 0.3MNaCl intakewas reduced in the groups that received PAR,
compared with the groups receiving saline injections, p b 0.01. In
contrast, daily water intake was not altered by surgery or treatment,
p = 0.128 (Fig. 3).
Paroxetine treatment mediated diureses in AR and SH animals
in weeks 1–3, and AR-saline presented with diureses only in week 4
(Fig. 4). Sodium excretion was greater in AR-PAR, as compared to SH-
PAR in week 1 (p = 0.034, Fig. 4). Natriureses were present in weeks
2–3 to AR-PAR and SH-PAR, as compared to saline groups (AR-saline
and SH-saline) and returned to control levels at week 4 (Fig. 4).
Kaliureses were present in week 2 for the AR-PAR compared to the
AR-saline groups (p = 0.037), (Fig. 4).
3.3. Blood pressure
Systolic blood pressure was similar in AR groups (AR-PAR: 165 ± 4
vs AR-saline: 166 ± 3 mm Hg, p = 0.212); however, PAR treatment
decreased BP in controls (SH-PAR: 138 ± 6 vs SH-saline: 156 ±
6 mm Hg, p = 0.008). Diastolic blood pressure was reduced in rats with
AR compared to SH, regardless of treatment status (AR-PAR: 72 ± 5 vs
SH-PAR: 85 ± 1 mm Hg, p = 0.03; AR-saline: 65 ± 4 vs SH-saline:
98 ± 3mmHg, p= 0.01, Fig. 5). Heart rate was not altered by condition
or treatment, with AR-PAR = 346.3 ± 10.5, SH-PAR = 327.4 ± 10.5,
AR-saline = 327.9 ± 12.8 and SH-saline = 343.4 ± 15.3 beats per
minute.
3.4. Heart weight
At the cessation of experiments, the animals were sacriﬁced, and the
hearts were removed, and the chambers were separated for compari-
sons. There were no signiﬁcant group differences between the AR
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127J.I.F. De Gobbi et al. / Physiology & Behavior 144 (2015) 124–128conditions for the atrium (p = 0.239), right ventricle (p = 0.108) or
bodyweight (p = 0.776), (Table 3). However, there was a bw differ-
ence in the SH groups between treatments (p = 0,037). Further-
more, the LV weight was higher in the AR groups than the SH
groups (p b 0.001), (Table 3).
4. Discussion
Our results indicate that chronic SSRI treatment with paroxetine
prevented LV systolic dysfunction and reduced daily sodium intake in
AR rats. In addition, an increase in natriureses was observed during
weeks 2–3 of treatment, with the values returning to basal levels at
week 4. Paroxetine reduced systolic pressure in the SH animals, with
no effect on AR rats. Diastolic pressure was reduced in AR, compared
to SH rats, and paroxetine did not alter this group difference. To the
best of our knowledge, no other treatment has been proven effective
in restoring shortening fraction by itself.
Depression is a frequent co-morbidity associatedwith heart diseases
[3–5]. It is interesting to note that the association between mood
disorders and cardiovascular disease is independent of other traditional
risk factors for cardiovascular diseases, such as hypertension, over-
weight status, hypercholesterolemia, or history of heart disease [3,4].
The SSRIs are the most commonly prescribed antidepressants through-
out the world due to dosage safety, good tolerability, and superior
safety when used in patients with heart disease given a reduction in
the probability of arrhythmias [6,8]. The accepted and hypothesized
mechanism of action for SSRIs is based on the downregulation of
somatodendritic 5-HT1A receptors. Serotonin neurotransmission is
involved in inhibition of sodium intake and excretion regulation. Intra-
cerebroventricular administration of 5-HT2 agonists in rats increases
sodium renal excretion [19]. Treatment with p-chlorophenylalanine, a
Table 3
Heart weight comparisons between groups.
Variables — 8
weeks
AR-PAR
n = 8
AR-saline
n = 7
SH-PAR
n = 8
SH-saline
n = 8
Body weight
(bw, g)
438.5 ± 16.0 420.4 ± 10.2 453.7 ± 12.0* 412.9 ± 13.1
A/100 g bw 0.027 ± 0.002 0.032 ± 0.002 0.025 ± 0.003 0.027 ± 0.002
RV/100 g bw 0.071 ± 0.005 0.069 ± 0.003 0.066 ± 0.004 0.059 ± 0.003
LV/100 g bw 0.276 ± 0.013* 0.320 ± 0.023* 0.210 ± 0.004 0.208 ± 0.006
A= atrium; RV= right ventricle and LV= left ventricle. Data are presented as themeans
± SEM. *Different from SH.
128 J.I.F. De Gobbi et al. / Physiology & Behavior 144 (2015) 124–128competitive and irreversible inhibitor of tryptophan hydroxylase, in-
duces natriorexigenic responses even for a paradoxical salt appetite
model that is dependent on beta-adrenergic stimulation [13]. Chemical
lesions of the raphe nuclei, which contain one of the largest populations
of serotonergic neurons, increase sodium intake [15]. Thus, our results
are in agreement with those previous studies. In the present results
we had reductions of daily sodium intake and natriureses in weeks
2–3 in both AR and SH animals. It is reasonably postulated that
PAR treatment increased the central 5-HT neurotransmission and
this augmentation produced the changes in sodium and excretion
behaviors.
Central 5-HT neurotransmission is also involved in the cardiovascu-
lar control. Interestingly, prosencephalic activation of the 5-HT3 agonist
receptor exerts an inhibitory action on the pressor part of the baroreﬂex
function [10]. Healthy individuals with family histories of coronary
arterial disease receiving PAR treatment presented with lower blood
pressure during psychosocial stress tests, suggesting a cardio-protective
effect [20]. Using SSRI to control panic syndrome in humans seems to be
beneﬁcial to the heart by increasing heart rate variability [9]. In patients
with post-myocardial infarction studies the SSRIs increase heart rate
variability [21] and improve outcomes [22]. On the other hand, antide-
pressant drugs, including tricyclic, serotoninergic or noradrenergic
drugs, may decrease heart rate variability [23,24]. Thereby there are
still controversies concerning the SSRIs on heart function, such as
heart disease etiology, dosing, administration route, and the type of
molecule used. Meanwhile, our results demonstrated a preservative
effect on systolic dysfunction following SSRI treatment, seen by the
improvement in fractional shortening in AR–PAR compared to AR–saline
at week 8. To the best of our knowledge no other treatment was able to
preserve the systolic function as it was seen in the present results.
Moreover, it is worth noting that the sphericity index did not change
after paroxetine treatment, indicating that LV geometric shape was still
affected by volume overload, whilst systolic function was preserved.
We might even speculate whether decreases in the sodium intake
would be beneﬁcial to heart function. The causal relationships linking
these observations might be complex, and our data do not allow us to
make further conclusions underlying this protective effect.
In conclusion, the data demonstrate that the antidepressant paroxe-
tine is beneﬁcial to cardiovascular function with exposure to volume
overload by preventing systolic dysfunction and reducing sodium
daily intake. These observations may relate to increased central 5-HT
neurotransmission. Future experiments would be needed to elucidate
the central involvement of 5-HT with circulating hormones that
improve cardiac function.
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